No Data
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is Still On The Mark Following 26% Share Price Bounce
Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%
Intra-Cellular Meets Main Goal in Late Stage Trial for Its Schizophrenia Treatment
Express News | Intra-Cellular Therapies Inc - Primary Endpoint Shows Longer Time to Relapse With Lumateperone
Express News | Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating Caplyta for the Prevention of Relapse in Patients With Schizophrenia
Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews
No Data
No Data